Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/2618
| Subject | Predicate | Object | Context |
|---|---|---|---|
| dailymed-drugs:2618 | rdf:type | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:2618 | rdf:type | dailymed-instance:drugs | lld:dailymed |
| dailymed-drugs:2618 | rdfs:label | Phenytoin (Suspension) | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:dosage | (NOT FOR PARENTERAL USE) Serum concentrations should be monitored and care should be taken when switching a patient from the sodium salt to the free acid form. The free acid form of phenytoin is used in phenytoin oral suspension and chewable tablets. All other phenytoin products are formulated with the sodium salt. Because there is approximately an 8% increase in drug content with the free acid form over that of the sodium salt, dosage adjustments and serum level monitoring may be necessary when switching from a product formulated with the free acid to a product formulated with the sodium salt and vice versa. General:Dosage should be individualized to provide maximum benefit. In some cases serum blood level determinations may be necessary for optimal dosage adjustments���the clinically effective serum level is usually 10-20 mcg/mL. With recommended dosage, a period of seven to ten days may be required to achieve steady-state blood levels with phenytoin and changes in dosage (increase or decrease) should not be carried out at intervals shorter than seven to ten days. Adult Dose: Patients who have received no previous treatment may be started on one teaspoonful (5 mL) of phenytoin oral suspension three times daily, and the dose is then adjusted to suit individual requirements. An increase to five teaspoonfuls daily may be made, if necessary. Pediatric Dose: Initially, 5 mg/kg/day in two or three equally divided doses, with subsequent dosage individualized to a maximum of 300 mg daily. A recommended daily maintenance dosage is usually 4 to 8 mg/kg. Children over 6 years and adolescents may require the minimum adult dose (300 mg/day). | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:descripti... | Phenytoin is related to the barbiturates in chemical structure, but has a five-membered ring. The chemical name is 5,5-diphenyl-2,4 imidazolidinedione, having the following structural formula: Each Teaspoonful (5 mL) of Suspension for Oral Administration Contains: 125 mg of phenytoin USP with a maximum alcohol content not greater than 0.6 percent. Inactive Ingredients: carboxymethylcellulose sodium, citric acid, FD&C Yellow No. 6, flavors, glycerin, magnesium aluminum silicate, polysorbate 40, purified water, sodium benzoate, sucrose, vanillin. May also contain sodium citrate to adjust pH. | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:clinicalP... | Phenytoin is an antiepileptic drug which can be useful in the treatment of epilepsy. The primary site of action appears to be the motor cortex where spread of seizure activity is inhibited. Possibly by promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation orenvironmental changes capable of reducing membrane sodium gradient. This includes the reduction of posttetanic potentiation at synapses. Loss of posttetanic potentiation prevents cortical seizure foci from detonating adjacent cortical areas. Phenytoin reduces the maximal activity of brain stem centers responsible for the tonic phase of tonic-clonic (grand mal) seizures. The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours. Steady-state therapeutic levels are achieved at least 7 to 10 days (5-7 half-lives) after initiation of therapy with recommended doses of 300 mg/day. When serum level determinations are necessary, they should be obtained at least 5-7 half-lives after treatment initiation, dosage change, or addition or subtraction of another drug to the regimen so that equilibrium or steady-state will have been achieved. Trough levels provide information about clinically effective serum level range andconfirm patient compliance and are obtained just prior to the patient's next scheduled dose. Peak levels indicate an individual's threshold for emergence of dose-related side effects and are obtained at the time of expected peak concentration. In a single dose bioequivalence study employing 24 healthy fasted male volunteers, the Alpharma phenytoin oral suspension was shown to be bioequivalent to that of the pioneer product, exhibiting equivalent rates and extent of phenytoin absorption. The T-of the Alpharma product was similar to that of the pioneer product, both exhibiting T-values ranging from 2.5 to 6 hours for greater than 70% of the study population. Optimum control without clinical signs of toxicity occurs more often with serum levels between 10 and 20 mcg/mL, although some mild cases of tonic-clonic (grand mal) epilepsy may be controlled with lower serum levels of phenytoin. In most patients maintained at a steady dosage, stable phenytoin serum levels are achieved. There may be wide interpatient variability in phenytoin serum levels with equivalent dosages. Patients with unusually low levels may be noncompliant or hypermetabolizers of phenytoin. Unusually high levels result from liver disease, congenital enzyme deficiency, or drug interactions which result in metabolic interference. The patient with large variations in phenytoin plasma levels, despite standard doses, presents a difficult clinical problem. Serum level determinations in such patients may be particularly helpful. As phenytoin is highly protein bound, free phenytoin levels may be altered in patients whose protein binding characteristics differ from normal. Most of the drug is excreted in the bile as inactive metabolites which are then reabsorbed from the intestinal tract and excreted in the urine. Urinary excretion of phenytoin and its metabolites occurs partly with glomerular filtration but, more importantly, by tubular secretion. Because phenytoin is hydroxylated in the liver by an enzyme system which is saturable at high plasma levels, small incremental doses may increase the half-life and produce very substantial increases in serum levels, when these are in the upper range. The steady-state level may be disproportionately increased, with resultant intoxication, from an increase in dosage of 10% or more. | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:activeIng... | dailymed-ingredient:Phenyto... | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:contraind... | Phenytoin oral suspension is contraindicated in those patients with a history of hypersensitivity to phenytoin or other hydantoins. | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:supply | Phenytoin Oral Suspension USP, 125 mg phenytoin/5 mL with a maximum alcohol content not greater than 0.6 percent, available in 8 fl oz bottles. Store at controlled room temperature 20��-25��C (68��-77��F). [See USP]. Protect from freezing and light. Dispense in a tight, light-resistant container as defined in USP. SHAKE WELL BEFORE USING. Manufactured byActavis Mid Atlantic LLC7205 Windsor Blvd.Baltimore, MD 21244 USA FORM NO. 0067Rev. 1/06VC2768 | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:genericDr... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:activeMoi... | dailymed-ingredient:Phenyto... | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:inactiveI... | dailymed-ingredient:water | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:inactiveI... | dailymed-ingredient:citric_... | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:inactiveI... | dailymed-ingredient:carboxy... | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:inactiveI... | dailymed-ingredient:sucrose | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:inactiveI... | dailymed-ingredient:glyceri... | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:inactiveI... | dailymed-ingredient:magnesi... | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:inactiveI... | dailymed-ingredient:flavors | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:inactiveI... | dailymed-ingredient:polysor... | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:inactiveI... | dailymed-ingredient:sodium_... | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:inactiveI... | dailymed-ingredient:vanilli... | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:inactiveI... | dailymed-ingredient:fd&c_ye... | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:inactiveI... | dailymed-ingredient:sodium_... | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:possibleD... | diseasome-diseases:691 | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:possibleD... | diseasome-diseases:176 | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:possibleD... | diseasome-diseases:488 | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:possibleD... | diseasome-diseases:1056 | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:possibleD... | diseasome-diseases:1257 | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:possibleD... | diseasome-diseases:1688 | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:possibleD... | diseasome-diseases:2541 | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:possibleD... | diseasome-diseases:2542 | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:possibleD... | diseasome-diseases:2990 | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:possibleD... | diseasome-diseases:3893 | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:possibleD... | diseasome-diseases:4131 | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:possibleD... | diseasome-diseases:372 | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:possibleD... | diseasome-diseases:2307 | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:possibleD... | diseasome-diseases:2321 | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:precautio... | General: The liver is the chief site of biotransformation of phenytoin; patients with impaired liver function, elderly patients, or those who are gravely ill may show early signs of toxicity. A small percentage of individuals who have been treated with phenytoin have been shown to metabolize the drug slowly. Slow metabolism may be due to limited enzyme availability and lack of induction; it appears to be genetically determined. Phenytoin should be discontinued if a skin rash appears . If the rash is exfoliative, purpuric, or bullous or if lupus erythematosus, Stevens-Johnson syndrome, or toxic epidermal necrolysis is suspected, use of this drug should not be resumed and alternative therapy should be considered. If the rash is of a milder type (measles like or scarlatiniform), therapy may be resumed after the rash has completely disappeared. If the rash recurs upon reinstitution of therapy, further phenytoin medication is contraindicated. Phenytoin and other hydantoins are contraindicated in patients who have experienced phenytoin hypersensitivity . Additionally, caution should be exercised if using structurally similar (eg, barbiturates, succinimides, oxazolidinediones and other related compounds) in these same patients. Hyperglycemia, resulting from the drug's inhibitory effects on insulin release, has been reported. Phenytoin may also raise the serum glucose level in diabetic patients. Osteomalacia has been associated with phenytoin therapy and is considered to be due to phenytoin's interference with vitamin D metabolism. Phenytoin is not indicated for seizures due to hypoglycemic or other metabolic causes. Appropriate diagnostic procedures should be performed as indicated. Phenytoin is not effective for absence (petit mal) seizures. If tonic-clonic (grand mal) and absence (petit mal) seizures are present, combined drug therapy is needed. Serum levels of phenytoin sustained above the optimal range may produce confusional states referred to as���delirium,������psychosis,���or���encephalopathy,���or rarely irreversible cerebellar dysfunction. Accordingly, at the first sign of acute toxicity, plasma levels are recommended. Dose reduction of phenytoin therapy is indicated if plasma levels are excessive; if symptoms persist, termination is recommended.<br/>Information for Patients: Patients taking phenytoin should be advised of the importance of adhering strictly to the prescribed dosage regimen, and of informing the physician of any clinical condition in which it is not possible to take the drug orally as prescribed, eg, surgery, etc. Patients should be instructed to use an accurately calibrated measuring device when using this medication to ensure accurate dosing. Patients should also be cautioned on the use of other drugs or alcoholic beverages without first seeking the physician's advice. Patients should be instructed to call their physician if skin rash develops. The importance of good dental hygiene should be stressed in order to minimize the development of gingival hyperplasia and its complications.<br/>Laboratory Tests: Phenytoin serum level determinations may be necessary to achieve optimal dosage adjustments.<br/>Drug Interactions: There are many drugs which may increase or decrease phenytoin levels or which phenytoin may affect. Serum level determinations for phenytoin are especially helpful when possible drug interactions are suspected. The most commonly occurring drug interactions are: *Moban' is a registered trademark of Endo Pharmaceutical Inc. Drug Enteral Feeding/Nutritional Preparations Interaction:Literature reports suggest that patients who have received enteral feeding preparations and/or related nutritional supplements have lower than expected phenytoin plasma levels. It is therefore suggested that phenytoin not be administered concomitantly with an enteral feeding preparation. More frequent serum phenytoin level monitoring may be necessary in these patients.<br/>Drug/Laboratory Test Interactions: Phenytoin may decrease serum concentrations of T4. It may also produce lower than normal values for dexamethasone or metyrapone tests. Phenytoin may cause increased serum levels of glucose, alkaline phosphatase, and gamma glutamyl transpeptidase (GGT). Care should be taken when using immunoanalytical methods to measure plasma phenytoin concentrations. Carcinogenesis:See WARNINGSsection for information on carcinogenesis.<br/>Pregnancy: Pregnancy Category D; See WARNINGS section.<br/>Nursing Mothers: Infant breast feeding is not recommended for women taking this drug because phenytoin appears to be secreted in low concentrations in human milk.<br/>Pediatric Use: See DOSAGE AND ADMINISTRATION section. | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:overdosag... | The lethal dose in pediatric patients is not known. The lethal dose in adults is estimated to be 2 to 5 grams. The initial symptoms are nystagmus, ataxia, and dysarthria. Other signs are tremor, hyperreflexia, lethargy, slurred speech, nausea, vomiting. The patient may become comatose and hypotensive. Death is due to respiratory and circulatory depression. There are marked variations among individuals with respect to phenytoin plasma levels where toxicity may occur. Nystagmus, on lateral gaze, usually appears at 20 mcg/mL, ataxia at 30 mcg/mL; dysarthria and lethargy appear when the plasma concentration is over 40 mcg/mL, but as high a concentration as 50 mcg/mL has been reported without evidence of toxicity. As much as 25 times the therapeutic dose has been taken to result in a serum concentration over 100 mcg/mL with complete recovery. Treatment:Treatment is nonspecific since there is no known antidote. The adequacy of the respiratory and circulatory systems should be carefully observed and appropriate supportive measures employed. Hemodialysis can be considered since phenytoin is not completely bound to plasma proteins. Total exchange transfusion has been used in the treatment of severe intoxication in pediatric patients. In acute overdosage the possibility of other CNS depressants, including alcohol, should be borne in mind. | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:genericMe... | Phenytoin | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:fullName | Phenytoin (Suspension) | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:adverseRe... | Central Nervous System: The most common manifestations encountered with phenytoin therapy are referable to this system and are usually dose-related. These include nystagmus, ataxia, slurred speech, decreased coordination, and mental confusion. Dizziness, insomnia, transient nervousness, motor twitchings, and headaches have also been observed. There have also been rare reports of phenytoin induced dyskinesias, including chorea, dystonia, tremor and asterixis, similar to those induced by phenothiazine and other neuroleptic drugs. A predominantly sensory peripheral polyneuropathy has been observed in patients receiving long-term phenytoin therapy. Gastrointestinal System:Nausea, vomiting, constipation, toxic hepatitis and liver damage. Integumentary System: Dermatological manifestations sometimes accompanied by fever have included scarlatiniform or morbilliform rashes. A morbilliform rash (measles-like) is the most common; other types of dermatitis are seen more rarely. Other more serious forms which may be fatal have included bullous, exfoliative or purpuric dermatitis, lupus erythematosus, Stevens-Johnson syndrome, and toxic epidermal necrolysis (see PRECAUTIONS section). Hemopoietic System: Hemopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin. These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. While macrocytosis and megaloblastic anemia have occurred, these conditions usually respond to folic acid therapy. Lymphadenopathy including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's disease have been reported (see WARNINGS section). Connective Tissue System: Coarsening of the facial features, enlargement of the lips, gingival hyperplasia, hypertrichosis, and Peyronie's disease. Immunologic: Hypersensitivity syndrome (which may include, but is not limited to, symptoms such as arthralgias, eosinophilia, fever, liver dysfunction, lymphadenopathy or rash), systemic lupus erythematosus, periarteritis nodosa and immunoglobulin abnormalities. | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:warning | Abrupt withdrawal of phenytoin in epileptic patients may precipitate status epilepticus. When in the judgment of the clinician the need for dosage reduction, discontinuation, or substitution of alternative anticonvulsant medication arises, this should be done gradually. In the event of an allergic or hypersensitivity reaction, more rapid substitution of alternative therapy may be necessary. In this case, alternative therapy should be an anticonvulsant not belonging to the hydantoin chemical class. There have been a number of reports suggesting a relationship between phenytoin and the development of lymphadenopathy (local or generalized) including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's disease. Although a cause and effect relationship has not been established, the occurrence of lymphadenopathy indicates the need to differentiate such a condition from other types of lymph node pathology. Lymph node involvement may occur with or without symptoms and signs resembling serum sickness, eg, fever, rash, and liver involvement. In all cases of lymphadenopathy, follow-up observation for an extended period is indicated and every effort should be made to achieve seizure control using alternative antiepileptic drugs. Acute alcoholic intake may increase phenytoin serum levels, while chronic alcoholic use may decrease serum levels. In view of isolated reports associating phenytoin with exacerbation of porphyria, caution should be exercised in using this medication in patients suffering from this disease.<br/>Usage In Pregnancy:<br/>Clinical::<br/>Preclinical:: Increased resorption and malformation rates have been reported following administration of phenytoin doses of 75 mg/kg or higher (approximately 120% of the maximum human loading dose or higher on a mg/mbasis) to pregnant rabbits. | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:indicatio... | Phenytoin oral suspension is indicated for the control of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures. Phenytoin serum level determinations may be necessary for optimal dosage adjustments . | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:represent... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:routeOfAd... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:2618 | dailymed-instance:name | Phenytoin | lld:dailymed |
| http://www4.wiwiss.fu-berli... | dailymed-instance:producesD... | dailymed-drugs:2618 | lld:dailymed |
| diseasome-diseases:691 | diseasome-instance:possible... | dailymed-drugs:2618 | lld:diseasome |
| diseasome-diseases:176 | diseasome-instance:possible... | dailymed-drugs:2618 | lld:diseasome |
| diseasome-diseases:488 | diseasome-instance:possible... | dailymed-drugs:2618 | lld:diseasome |
| diseasome-diseases:1056 | diseasome-instance:possible... | dailymed-drugs:2618 | lld:diseasome |
| diseasome-diseases:1257 | diseasome-instance:possible... | dailymed-drugs:2618 | lld:diseasome |
| diseasome-diseases:1688 | diseasome-instance:possible... | dailymed-drugs:2618 | lld:diseasome |
| diseasome-diseases:2541 | diseasome-instance:possible... | dailymed-drugs:2618 | lld:diseasome |
| diseasome-diseases:2542 | diseasome-instance:possible... | dailymed-drugs:2618 | lld:diseasome |
| diseasome-diseases:2990 | diseasome-instance:possible... | dailymed-drugs:2618 | lld:diseasome |
| diseasome-diseases:3893 | diseasome-instance:possible... | dailymed-drugs:2618 | lld:diseasome |
| diseasome-diseases:4131 | diseasome-instance:possible... | dailymed-drugs:2618 | lld:diseasome |
| diseasome-diseases:372 | diseasome-instance:possible... | dailymed-drugs:2618 | lld:diseasome |
| diseasome-diseases:2307 | diseasome-instance:possible... | dailymed-drugs:2618 | lld:diseasome |
| diseasome-diseases:2321 | diseasome-instance:possible... | dailymed-drugs:2618 | lld:diseasome |